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A B S T R A C T
The effect of breathing parameters on the airway deposition of the inhaled aerosols with known size was in-
tensively studied in the literature. However, in the case of dry powder aerosol drugs both the quantity and
quality of the particles emitted by the inhaler and inhaled by the patients is a complex function of the patient's
breathing parameters, which in turn depend also on the disease severity and current status of the patient. The
aim of this study was to evaluate the impact of breathing parameters, gender, age, symptoms and exacerbation
history related disease severity (GOLD groups) of chronic obstructive pulmonary disease (COPD) patients on the
lung dose of four different drugs emitted by three DPIs (dry powder inhalers). Breathing profiles of 47 COPD
patients were recorded while they inhaled through Turbuhaler®, Breezhaler® and Genuair® inhalers. Patient
specific emitted doses and particle size distributions were determined for Symbicort® Turbuhaler®, Onbrez®
Breezhaler®, Seebri® Breezhaler® and Bretaris® Genuair® aerosol drugs. Airway deposition was quantified by a
validated whole respiratory tract particle deposition model. Correlation analysis of the lung doses with breathing
parameters through the devices and with standard spirometric parameters was performed. The effects of gender,
age and degree of disease severity (GOLD groups) on the lung doses were also studied by statistical analysis.
Mean values and distributions of the deposited lung doses proved to be both drug and device specific, yielding
24.2 (± 7.8), 22.6 (± 3.6), 34.2 (± 4.8) and 23.9 (± 5.4) % values for Symbicort®, Onbrez®, Seebri® and
Bretaris®, respectively. Drugs with flow rate sensitive emitted dose and emitted particle size distribution ex-
hibited higher intersubject variability of the lung doses. The degree of correlation of lung doses with breathing
parameters through the devices was also drug specific. Correlation with flow rate was the strongest for
Symbicort® Turbuhaler®. Longer breath-hold increased the lung dose of all the studied drugs. Correlations of
lung dose with standard spirometric parameters was generally weaker than its correlation with the parameters
measured when inhaling through the devices. Men had higher lung deposition than women, younger patients
had higher deposition than older ones and patients with less severe disease higher doses than those with more
severe COPD, but the differences were statistically significant only upon gender and only in case of Symbicort®
and Seebri®. Patients with better inhalation parameters are likely to have higher lung deposition when inhaling a
drug with emitted dose and particle size distribution sensitive to the inhalation flow rate. At the same time,
patients with lower lung capacity show better deposition results when inhaling from inhalers emitting a more
constant amount of drug and particles with more stable aerodynamic characteristics. A more powerful inhalation
significantly increases the lung dose for the drug emitted by Turbuhaler®, while long breath-hold is likely to
yield significantly higher deposition for drugs emitted by Breezhaler® and Genuair®. Lung doses of two different
drugs dispensed in the same inhaler can be significantly different.
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1. Introduction
Airway deposition of dry powder inhalation drugs is a result of a
complex patient-inhaler-particle interaction. Breathing capabilities of
the patient influence the amount of active ingredient emitted by a DPI
and also its size distribution (Bagherisadeghi et al., 2017;
Chapman et al., 2011; Chrystyn and Niederlaender, 2012). By the same
token, the internal geometry and flow resistance of the device affect the
inhalation flow rate through the inhaler, the flow structure inside the
device and the number of particle-wall collisions determining the de-
gree of disaggregation and detachment of the drug particles from their
carriers (Cui and Sommerfeld, 2019; Donovan et al., 2012). Once in-
haled, the airway transport and deposition of the drug depend on the
drug particle characteristics, airflow parameters and airway geometry
(Hofmann, 2011). Due to the large and continuously increasing number
of DPI device - active ingredient combinations and the inherent inter-
subject variance of the relevant spirometric parameters (Crapo and
Jensen, 2003), it is a real challenge to find the most appropriate device
and drug for each patient ensuring an effective airway deposition. One
of the solutions that may help the choice of an appropriate device and
drug would be to predict their airway deposition. A sufficiently high
lung deposition is needed to reach the targeted receptors of the drugs. It
should be recognized however that inhaler choice is a multifactorial
decision, and the device that theoretically provides optimal deposition
for a given patient may not be appropriate for some other reason (e.g.
the patient cannot learn its adequate usage). Nevertheless, the avail-
ability of the predicted deposition values would help the medical pro-
fessionals in a more knowledge based device choice.
Aerosol particles deposit in the airways mostly due to three me-
chanisms, namely inertial impaction, gravitational settling and thermal
diffusion (Balásházy et al., 1990). While for the size range of current
aerosol drugs deposition by Brownian (thermal) motion can be ne-
glected, impaction and sedimentation are strongly influenced by par-
ticle size (or size distribution, in case of polydisperse systems). How-
ever, breathing parameters play also a major role in the emission and
deposition of particles. In the case of DPI drugs they influence the
quantity and the aerodynamic properties of the drug particles and also
their fate after the inhalation. The relationship between the main in-
halation parameters and the fraction of particles depositing in different
regions of the airways is complicated even for the case when the size of
the particles does not depend on the breathing parameters (e.g. pMDI
drugs), and becomes more complex when it comes to DPI drugs
(Weers and Clark, 2017). In addition, different breathing parameters
have varying influence on the deposition. For instance, deposition by
impaction is more influenced by the magnitude of flow rate, and de-
position by sedimentation is influenced by the time available for de-
position. Moreover, the relative importance of the different breathing
parameters is inhaler and drug specific. Therefore, it is important to
establish the dependence of all the relevant breathing parameters in
case of multiple device-drug pairs. This may help in the selection of the
appropriate device for every patient. In addition, if the patient cannot
perform the whole breathing manoeuvre correctly, it would be useful to
advise her/him on which elements of the manoeuvre concentrate more
to obtain higher lung deposition.
Present work proposes to use realistic breathing data recorded on
COPD patients with different degrees of disease severity while they
inhaled through commonly used DPI devices and simulate their airway
deposition distribution. The aim of this study is contribute to the
knowledge on the personalized therapy by using the patient-specific
deposition values to evaluate the relative importance of all the relevant
breathing parameters in drug deposition and to find correlations be-
tween gender, age and disease groups and the lung deposition of the
aerosol drugs.
2. Methods
In this work the analysis of the effect of different breathing para-
meters on the deposition distribution of the studied drugs was com-
pleted by identifying the key breathing parameters, simulating the
aerosol deposition distributions and performing statistical analyses. The
determination of the amount of drug depositing in different anatomical
regions of the human airways was based on the measurement of in-
dividual inhalation profiles of COPD patients, computation of patient-
specific emitted drug doses and particle size distributions and tracking
of the inhaled drug particles until they deposited or left the airways by
exhalation by the use of a validated deposition model. In the followings
these steps will be described in more details.
2.1. Measurement of the inhalation profiles of COPD patients
Standard spirometric measurements were performed on 47 adult
volunteer COPD patients (19 females and 28 males). Inhalation profiles
of the same subjects were also acquired while they inhaled through
Turbuhaler®, Breezhaler® and Genuair® DPI inhalers (ethical approval
nr. 76-1-20/2017). For this purpose, a hand-held spirometer (Otthon
Idegen™ mobile spirometer of Thor Laboratories) has been used. The
spirometer was inserted between the inhaler and the mouth of the pa-
tients as shown in Fig. 1. The inhalers were realistic but emptied, thus
no active substance was inhaled by the patients during the experiments.
In case of Breezhaler® an empty capsule was used. Emptying the devices
did not significantly affect their internal flow resistance. In addition to
the registration of breathing profiles, the breath-hold time after the
inhalation was also measured for each patient. The participating pa-
tients were volunteers; their written consent was obtained. The parti-
cipants were instructed on the use of each inhaler by the same person
according to the official patient information leaflets. The patients were
previously categorized into GOLD (Global Initiative for Chronic Ob-
structive Lung Disease) groups (GOLD, 2019). A number of 26 patients
were classified into GOLD B, 7 patients into GOLD C and 14 patients
into the GOLD D group.
2.2. Selected inhalation parameters through the devices
The individual breathing profiles acquired while the patients in-
haled through DPI devices are characterized by several breathing
parameters. The first step of studying the relative importance of dif-
ferent breathing parameters in airway deposition of aerosol drugs was
the identification of the relevant inhalation parameters. Inhalation flow
rate is a key quantity regarding the emission of the drug from a DPI
(Chrystyn et al., 2015) but also regarding its deposition within the
airways (Weers and Clark, 2017). The flow rate is not constant during
Fig. 1. Experimental setup of the inhalation profile measurements of COPD
patients while inhaling through the selected inhalers.
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drug inhalation, but it is time dependant. Historically, attention was
paid to the maximum value of flow rate through the device (PIFdev).
However, mean flow rate (denoted by Q in this study) can also be a
significant parameter characterizing the strength of the inhalation. It is
also a useful parameter because most of the in vitro measurements
aiming at the aerodynamic characterization of DPI drugs (impactor
measurements) use constant flow rates. Due to the lack of impactor
measurements using the realistic inhalation profile of each patient,
mean flow rate of the patient can be used to determine the patient
specific emitted doses and particles size distributions (Farkas et al.,
2016). Since different sets of values of the inhaled volume (IV) and
inhalation time (tin) may yield the same mean flow rate, it is plausible
to study the dependence of lung deposition also on these parameters (IV
and tin). Lung deposition depends on the inhaled air volume directly,
but also indirectly through the effect of the inhaled volume on the
aerodynamic characteristics of the emitted DPI drugs (Janson et al.,
2017; Buttini et al., 2016). A number of authors have drawn the at-
tention on the importance of ramp-up (acceleration) of the inspired
flow (e.g. Ung and Chan, 2016; Chrystyn et al., 2015). However, the
impact of flow acceleration on lung deposition could not be analysed in
this study due to the lack of knowledge regarding the dose delivery
performance of the studied aerosol drugs corresponding to the special
flow ramp-up of each participating patient, which would require a
series of in vitro examinations.
2.3. Calculation of the patient-specific emitted doses and particle size
distributions
Currently, several drugs dispensed in Turbuhaler®, Breezhaler® and
Genuair® inhalers are available, which may have different aerodynamic
properties and airway deposition. In this study we selected four drugs
for which sufficient data is available to consider patient specific emitted
doses and particle size distributions. The four drugs were Symbicort®
Turbuhaler®, Onbrez® Breezhaler®, Seebri® Breezhaler® and Bretaris®
Genuair®. Symbicort® Turbuhaler® (AstraZeneca) is a drug containing
anti-inflammatory inhalation corticosteroid (ICS, budesonide) and long-
acting beta-agonist bronchodilator (LABA, formoterol fumarate dihy-
drate) active ingredients. Onbrez® Breezhaler® (Novartis) is a long-
acting beta-agonist bronchodilator containing indacaterol, while
Seebri® Breezhaler® (Novartis) contains glycopyrronium bromide,
which is a long-acting muscarinic antagonist bronchodilator. Bretaris®
Genuair® (Berlin-Chemie Menarini) is also a long-acting muscarinic
antagonist bronchodilator drug containing aclidinium bromide as ac-
tive substance.
Patient-specific emitted doses (ED) were determined based on the
measurements available in the open literature. In the published works
emitted doses are provided for different constant inhalation flow rate
values. Deducing mathematical expressions of the emitted doses as
functions of inhalation flow rate allowed us to assign an emitted dose to
each patient based on her/his individual mean inhalation flow rate (Q).
Fig. 2 demonstrates the experimentally measured emitted doses at
different flow rates for the above four aerosol drugs and the power
functions fitted by us. The measured emitted dose values of Symbicort®
Turbuhaler® were derived from the works of de Boer et al. (2015),
Bagherisadeghi et al. (2017), Chrystyn et al. (2015),
Buttini et al. (2016) and Haikarainen et al. (2017). In case of Onbrez®
Breezhaler® the measured dose delivered by the device was retrieved in
Pavkov et al. (2010) and Chapman et al. (2011), while emission data
regarding Seebri® Breezhaler® was taken from Colthorpe et al. (2013).
Finally, the emission characteristics of Bretaris® Genuair® were gath-
ered from Newman et al. (2009) and Block et al. (2010).
A similar method has been applied for the determination of patient
specific size distribution of the emitted particles based on measurement
results and individual inhalation flow rates. The personalized size dis-
tributions were reconstructed from the available information on the
MMADs (mass median aerodynamic diameter), GSDs (geometric
standard deviation), fine particle fractions (FPF, fraction of the metered
dose provided by particles with diameter < 5 μm) and aerosolized
fractions (AF, defined here as the fraction of the metered dose re-
presented by smaller particles which deposit on the impactor plates and
on the filter). By the help of AF it is possible to determine the large
particle fraction (LPF), which is composed of particles depositing in the
impactor inlet throat and in the pre-separator, by the formula:
LPF=ED-AF. Fig. 3 demonstrates the experimentally measured FPFs at
different flow rates for the four considered drugs and the linear func-
tions fitted to them. By the help of these functions the patient specific <
5 μm size fraction can be determined if the inhalation flow rate of the
patient is known. The measured values in Fig. 3 were derived from the
published literature. The references coincided with those mentioned at
the emitted doses for Onbrez® Breezhaler® and Seebri® Breezhaler® and
they were complemented by the works of Johal et al. (2013),
Tarsin et al. (2004), Tarsin et al. (2006), Hoppentocht et al. (2014),
Corradi et al. (2014), Assi et al. (2006) and Borgström et al. (2005) in
the case of Symbicort® Turbuhaler® and by the paper of
Gjaltema et al. (2013) in the case of Bretaris® Genuair®.
2.4. Modelling of individual airway deposition distributions
The recorded breathing profiles and the individual-specific emitted
doses and particle size distributions were used to compute the doses
deposited in the extrathoracic airways and in the lungs of the patients.
For this purpose, a whole respiratory tract deposition model was used.
The model tracks large numbers of inhaled particles (typically 100,
000) until they deposit or leave the airways by exhalation. The initial
version of the aerosol particle deposition model was developed by
Koblinger and Hofmann (1985). In the original model the deposition of
particles in the extrathoracic airway region is estimated based on em-
pirical formulas derived by Cheng (2003). However, Cheng's formulas
and other similar relationships established based on experimental
measurements (e. g. Stahlhofen et al., 1989; Rudolf et al., 1994;
Heyder et al., 1986) were not designed for use with DPI's. It is a par-
ticularity of the inhalation from DPI's that the deposition in the oral
cavity and throat is influenced by the high velocity jet flow exiting the
inhaler. Lin et al. (2001) have demonstrated that the diameter of the
mouthpiece has a significant effect on the oral deposition with lower
deposition for larger nozzle diameter. DeHaan and Finlay (2004) de-
rived oral deposition formulas accounting for the nozzle diameter and
turbulence. However, their formulas can be used only if the size dis-
tribution of the particles emitted by DPI is known. In practice, in
compliance with the protocols described in the Pharmacopoeias
(Council of Europe, 2020; United States Pharmacopeia, 2020), aerosol
drug particle size measurement is performed by impactors preceded by
a 90° bent tube (throat) and sometimes a pre-separator. The total mass
of particles depositing in the impactor throat is measured, but in-
formation is missing regarding their size distribution, which is de-
termined only for the particles entering the impactor. In this study, we
considered that the experimentally measured mass of drug depositing in
the impactor throat would deposit also in the mouth-throat region of
the patients inhaling the same drug with the same inhalation flow rate.
In addition, the empirical formula of Stahlhofen et al. (1989) was ap-
plied to estimate the mass (dose) of drug depositing in the laryngeal
region which is not included in the impactor measurements. Indeed, the
authors of the work stated that in their experiments the oral cavity and
pharyngeal deposition was negligible, thus their model yielded an es-
timate primarily of the laryngeal deposition. Fig. 4 demonstrates that
this approach ensures a realistic estimation of the extrathoracic drug
deposition. In the tracheobronchial and acinar airway regions we ap-
plied the original model of Koblinger and Hofmann (1985). In this
model the fate of the inhaled particles is predicted in a stochastic lung
structure with morphometric characteristics (tube lengths and dia-
meters, branching and gravity angles) based on a database of Raabe
et al. (1976). In the acinar part of the airways the particles are tracked
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in a geometry reconstructed from the description of Haefeli-Bleuer and
Weibel (1988). The intersubject variability of the airway geometry was
taken into account by the stochastic nature of the model and by in-
dividual scaling of the airways based on the available anthropometric
(height) and volumetric (functional residual capacity, tidal volume)
data of the patients. The changes in airway geometry due to the disease
were also accounted for. The bronchial airways were contracted with
different probabilities and the extent of contraction was dependant on
the disease severity. The conductive part of the acinar airways could
also be contracted depending on the disease severity. The dilatation of
the alveoli in the acinar region was also taken into account. The
probability and extent of contraction of the bronchial airways and the
conductive part of the acinar airways and the probability and extent of
dilatation of the alveoli in the acinar region are listed in Tables A1 – A2
of the Supplementary Material.
2.5. Model validation
The numerical model described in the previous section was vali-
dated against experimental deposition data of different types of aero-
sols, including therapeutic ones (Farkas et al., 2015, 2016, 2017;
Farkas et al., 2018). In addition, before performing the simulations the
deposition model was tested for the inhalers and active ingredients
considered in this study. This task was accomplished by comparing the
results of available scintigraphic deposition measurements and nu-
merical estimations with the corresponding simulation results obtained
by our model for the same set of input breathing parameters and aerosol
characteristics.
Borgström et al. (1994) have measured upper airway and lung de-
position fractions of budesonide emitted by Turbuhaler® of ten (five
women) healthy subjects whose FEV1 ranged between 83 and 127% of
predicted. The peak inhalation flows of the patients were between 53
and 64 L/min, inhaled volume between 2.07–4.97 L and breath-hold
time after the inhalation was 10 s. Aerodynamic characteristics of the
emitted particles corresponded to 60 L/min inhalation flow rate. Their
size distribution was determined by a multistage liquid impinger.
Chapman et al. (2011) evaluated the regional (oropharyngeal and in-
trathoracic) deposition of indacaterol dispensed in Breezhaler® in seven
COPD patients (4 women) whose peak flow varied between 47 and
99 L/min, inhaled volume ranged between 1.0–2.2 L, inhalation time
between 1.3–3.2 s and breath-hold time was 10 s. Particle size dis-
tributions were determined for the individual breathing profiles by a
Next Generation Impactor. Contrary to the studies presented above,
drug deposition was not measured but quantified by the help of an open
source model (ICRP66 model). Colthorpe et al. (2013) assessed extra-
thoracic and lung deposition fractions of glycopyrronium emitted by
Fig. 2. Measured emitted dose values of Symbicort® Turbuhaler® (upper left), Onbrez® Breezhaler® (upper right), Seebri® Breezhaler® (lower left) and Bretaris®
Genuair® (lower right) as a function of inhalation flow rate derived from the open literature and corresponding power function fits. The fitted functions were used for
the determination of patient specific emitted doses (Symbicort®: ED=10.6 × Q0.46, Onbrez®: ED=27.77×Q0.25, Seebri®: ED=52.93×Q0.11, Bretaris®:
ED=49.13×Q0.14). All emitted doses are expressed as a percent of metered dose. ED – emitted dose, Q – inhalation flow rate.
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Breezhaler® in the same seven COPD patients who were also the sub-
jects of the work of Chapman et al. (2011). Particle aerodynamic
characteristics were determined for the individual breathing profiles by
a Next Generation Impactor. Airway deposition was simulated by the
ICRP66 model. Finally, Newman et al. (2009) experimentally measured
extrathoracic and lung deposition fractions of the inhaled aclidinium
bromide in 12 healthy male volunteers with FEV1 between 84 and
121% of predicted. Their average peak flow through the device was 79
(± 9.4) L/min, inhaled volume 3.91 (± 0.72) L and breath-hold time
was 9.7 (± 0.6). The aerodynamic particle size distribution was de-
termined by a 5-stage multistage liquid impinger at 90 L/min airflow
rate.
Fig. 4 depicts the results of the above works in comparison with the
deposition values of present simulations performed for the same inputs.
As the figure demonstrates, there is a good agreement in terms of re-
gional deposited doses. The good match indicates that our computa-
tional model is appropriate for the simulation of the deposition of
aerosol drugs in general, and for the prediction of regional doses of the
modelled active ingredients in particular.
2.6. Statistical analysis
An analysis of the correlation of the computed lung doses with the
breathing parameters characterizing the inhalation through the selected
devices (Q, tb-h, IV, tin, PIFdev) was performed. The strength of the
correlation was expressed in terms of Pearson coefficients and any
correlation was considered significant when p<0.05. In addition, the
correlation of lung deposition with baseline spirometric breathing
parameters expressing the breathing status of the patient (expiratory
volume at the end of the first second of forced exhalation: FEV1, forced
vital capacity: FVC, Tiffeneau index: FEV1/FVC, peak inhalation flow:
PIF, peak expiratory flow PEF, inspiratory vital capacity: IVC) was
studied. For the sake of clarity, it is worth noting that PIF denotes the
peak inhalation flow measured by standard spirometry, while PIFdev is
the peak inhalation flow measured while inhaling through the device
(PIFdev<PIF). By the same token, mean values of lung doses char-
acteristic of different age, gender and GOLD groups were analysed
conducting two-sample t-tests. Two age groups were formed. The cut-
off age was 65 years, because most of the developed countries have
accepted the chronological age of 65 years as a definition of 'elderly' or
older person. Two groups were analysed also upon the classification of
patients based on symptoms and exacerbation history. The first group
(GOLD B) included 26 patients and the second group (GOLD C and D)
21 patients. All statistical analyses have been performed by the appli-
cation of OriginPro 2018 (version b9.5.0.193, OriginLab Corporation,
Northampton, Massachusetts, USA).
Fig. 3. Measured fine particle fraction values of Symbicort® Turbuhaler® (upper left), Onbrez® Breezhaler® (upper right), Seebri® Breezhaler® (lower left) and
Bretaris® Genuair® (lower right) at different inhalation flow rates gathered from the open literature and the corresponding linear fits. The fitted functions were used
for the determination of patient specific < 5 μm size fractions (Symbicort®: FPF = 0.58×Q + 0.28, Onbrez®: FPF = 0.25×Q + 13.6, Seebri®:
FPF = 0.26×Q + 29.89, Bretaris®: FPF = 0.13×Q + 19.58). FPF – fine particle fraction, Q – inhalation flow rate, r – correlation coefficient.
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3. Results and discussion
In this section, the results of patient specific airway deposition si-
mulations of the studied drugs will be presented. The relationships
between the lung doses of the patients and their individual breathing
parameters through the selected devices will be analysed. The corre-
lations between the lung dose and baseline spirometric parameters will
also be presented. Finally, the future perspectives of patient specific
device-drug pair choice and optimization of drug delivery based on the
predicted lung depositions will be discussed.
3.1. Distribution of individual-specific lung doses of the selected aerosol
drugs
As a first step, the patient specific emitted doses and particle size
distributions were calculated based on the fitted formulas deduced and
presented in the methods sections (see Figs. 2 and 3). The average
values and the ranges of the computed emitted doses (ED, as a percent
of metered dose) and mass median aerodynamic diameters (MMAD) of
the 47 patients are presented in Table 1.
The distribution of the lung doses of 47 COPD patients obtained
based on the individual breathing parameter values and patient specific
emitted doses and aerosol size distributions can be seen in Fig. 5. Drug
doses deposited in the lungs are expressed as a percent of the metered
dose. Mean values and standard deviations of the lung dose for a given
drug are also demonstrated. A comparison of the deposition values in
Figs. 4 and 5 reveals that lung deposition fractions of realistic patients
can be lower than the values measured by scintigraphy where the vo-
lunteers are often healthy subjects. Indeed, the mean values of the
calculated lung doses in Fig. 5 agree well with the mean values of the
lung deposition fractions of Onbrez® Breezhaler® and Seebri® Breez-
haler® which were measured in COPD patients, but the present values
are lower for Symbicort® Turbuhaler® and Bretaris® Genuair® where the
volunteers of the scintigraphic studies were healthy subjects. Therefore,
one of the outcomes of the present work is that scintigraphic lung de-
position values of different aerosol drugs that can be retrieved in the
open literature represent mostly the upper limit of lung doses, espe-
cially if the measurements were performed on healthy volunteers.
Besides the mean values of the lung dose, it is worth analysing their
intersubject variability, as well. Based on Fig. 5, while for some drugs
the majority of lung doses fall into a relatively narrow interval (On-
brez®, Seebri® and partly Bretaris®), for other drugs the inter-individual
spread is more consistent (e.g. Symbicort® Turbuhaler®). The inter-
subject variability of the lung dose is strongly related to the flow rate
dependence of the emitted dose and particle size distribution. It is clear
from Figs. 2 and 3 that both the amount of the emitted drug and its size
Fig. 4. Comparison of experimental deposition (filled columns) and the corresponding simulation results for budesonide (upper left), indacaterol (upper right),
glycopyrronium (lower left) and aclidinium bromide (lower right) active ingredients. All deposition fractions are provided as a percent of the metered dose.
Table 1
Mean values and ranges of the computed individual specific emitted doses and
mass median aerodynamic diameters of the emitted aerosols for Symbicort®
Turbuhaler®, Onbrez® Breezhaler®, Seebri® Breezhaler® and Bretaris® Genuair®
drugs. ED – emitted dose, MMAD – mass median aerodynamic diameter.
ED (%) MMAD (μm)
Symbicort® Turbuhaler® 62.5 (43.4–86.3) 2.4 (1.3–3.2)
Onbrez® Breezhaler® 77.6 (65.1–93.2) 3.0 (1.9–3.6)
Seebri® Breezhaler® 83.3 (76.5–96.6) 2.7 (2.5–2.8)
Bretaris® Genuair® 82.9 (71.0–90.2) 2.5 (2.2–2.7)
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distribution are the most sensitive to the variance of inhalation flow
rate in case of Symbicort® Turbuhaler®. Fig. 5 demonstrates that for this
drug the inter-individual variance of lung dose is also the highest. It is
worth noting that Onbreez® and Seebri® provided different deposition
distributions both in terms of mean values and standard deviations,
though the two drugs were emitted by the same device. The fraction of
the metered dose depositing in the lungs of the same COPD patients is
in average 1.5 times higher for Seebri® than for Onbreez®. As the par-
ticles are emitted by the same device, the difference is probably due to
the different compositions and different formulation processes of the
two drugs. It is well-known that unlike Onbreez®, Seebri® does contain
MgSt, an ingredient controlling the adhesive forces between the active
substance and the carrier (Jetzer et al., 2018). This may also be the
reason why Seebri® has a much higher fine particle fraction (see Fig. 3).
This translated in higher lung doses in case of Seebri® but also in a
higher spread of the individual lung dose values. It is also worth noting
that Genuair® has a built in mechanism with the role of blocking the
emission of drug until the inhalation flow rate of the patient exceeds the
Fig. 5. Distribution of the simulated individual lung doses in case of Symbicort® Turbuhaler® (upper left), Onbrez® Breezhaler® (upper right), Seebri® Breezhaler®
(lower left) and Bretaris® Genuair® (lower right) aerosol drugs. The corresponding mean extrathoracic doses were 33%, 22.6%, 36% and 51.2%, respectively.
Table 2
Minimum and maximum values of the calculated lung doses (as a percent of metered dose) and the corresponding breathing data through Turbuhaler®, Breezhaler®
and Genuair® for Symbicort® Turbuhaler®, Onbrez® Breezhaler®, Seebri® Breezhaler® and Bretaris® Genuair® aerosol drugs. Q –mean inhalation flow rate through the
inhaler, tb-h – breath-hold time, IV – inhaled volume, tin – inhalation time, PIFdev – peak inhalation flow through the inhaler.
Flow resistance (Pa0.5 s L−1) Lung dose (%) Q (L/min) tb-h (s) IV (L) tin (s) PIFdev (L/min)
Symbicort® Turbuhaler® min: 8.9 17.1 3 1.2 4.3 37.2
64.2 max: 42.4 91.1 5 3.4 2.2 216.6
Onbrez® Breezhaler® min: 9.7 126.6 5 3.7 1.7 209.4
36.2 max: 29.2 59.3 12 3.6 3.7 75.0
Seebri® Breezhaler® min: 25.9 37.3 3 1.3 2.1 66.6
36.2 max: 44.7 89.6 18 2.5 1.7 171.6
Bretaris® Genuair® min: 18.6 17.5 3 1.2 4.3 38.4
58.4 max: 39.8 87.3 5 3.6 2.5 181.7
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threshold of 40–45 L/min (Magnussen et al., 2009; Chrystyn and
Niederlaender, 2012; der Palen, 2014). The aim of this mechanism is to
obtain a high and relatively constant emitted dose and also to ensure
that the airflow is sufficiently strong to detach the drug particles from
their lactose carriers. In this study there were six patients whose PIFdev
was around the threshold value. Although their deposition values were
included in the distribution in Fig. 5, in reality the drug may not be
released for some of them. Since the lung dose values for these patients
are low, the distribution of lung doses in Fig. 5 corresponding to Bre-
taris® Genuair® may be even narrower (starting from 18% of the me-
tered dose). If these patients were discounted, the mean (± stdv) lung
dose of Genuair® would be 25.2 (± 4.4)%. Table 2 presents the ex-
treme values of lung doses for the four drugs and the breathing para-
meters corresponding to them. Airflow resistances of the DPI inhalers
provided by Ciciliani et al. (2017) are also presented in the table. As the
table demonstrates, the deposition of each drug could be improved
consistently by optimizing the breathing. The lung doses of the patients
with the highest lung deposition are 1.7 (Seebri® Breezhaler®) - 4.8
(Symbicort® Turbuhaler®) times higher than the lowest lung doses of
the same drug. Another aim of the table is to reveal in what conditions
the same drug yields low or high lung deposition values after identical
patient instructions. Based on the data in Table 2, deposition of Sym-
bicort® Turbuhaler® was the highest for the patient who inhaled very
forcefully and the lowest for the patient who had a weak inhalation. To
the contrary, Onbrez® Breezhaler® had the lowest lung deposition for a
patient with very high mean inhalation flow rate which caused a high
upper airway deposition by impaction of drug particles. Interestingly,
the same patient had the highest lung dose of Symbicort® and the
lowest lung dose of Onbrez®. It means that the same strong inhalation
of the same person led to high emitted dose and small inhaled particles
with high lung deposition of Symbicort®, but to a too high flow rate
through Breezhaler® (which has a much lower flow resistance) causing
high throat deposition. This highlights again the importance of patient
tailored drug and device choice. The highest lung dose of Onbrez® was
achieved by a patient with sufficiently high (but not too high) mean
inhalation flow rate, high inhaled volume and long breath-hold. Simi-
larly, sufficiently high mean flow rate and very high breath-hold time
caused the highest deposition of Seebri®. In case of Bretaris® high mean
flow rate and high inhaled volume made the difference.
3.2. The influence of device and patient specific breathing parameters on the
lung dose
As Fig. 5 and Table 2 suggest, the sensitivity of the lung dose to
different breathing parameters is drug and inhalation device specific.
However, the exact correlations can be revealed only by statistical
analyses. Figs. 6–10 depict the dependence of lung dose of Symbicort®
Turbuhaler®, Onbrez® Breezhaler®, Seebri® Breezhaler® and Bretaris®
Genuair® on different breathing parameters characterizing the inhala-
tion of the patients through the three devices. The values of Pearson
coefficient and the nature of the correlation (significant or not) are also
summarized in Table 3.
It is evident from Table 3 and Figs. 6–10 that for Symbicort® Tur-
buhaler® the lung dose correlates strongly with the mean flow rate (Q)
and the correlation with PIFdev and IV is also good and significant.
However, the amount of this drug depositing in the lungs of COPD
Fig. 6. Dependence of lung dose on the mean inhalation flow rate (Q) through the device in case of Symbicort® Turbuhaler® (upper left panel), Onbrez® Breezhaler®
(upper right panel), Seebri® Breezhaler® (lower left panel) and Bretaris® Genuair® (lower right panel). All the lung doses are expressed as a percent of metered dose.
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patients does not correlate significantly with tin and tb-h, though longer
breath-hold increases the lung dose to some extent. The good correla-
tion with flow rate can be attributed to the strong dependency of the
emitted dose and fine particle fraction on this parameter (see Figs. 2
and 3). Lung deposition of Onbrez® Breezhaler® exhibited the weakest
correlation with the inhalation parameters considered, except the
breath-hold time which was in moderate and significant correlation
with the lung dose. In case of Seebri® Breezhaler® there was moderate
or good and significant correlation with all the parameters, except for
tin, which did not correlate significantly with the lung dose. The dif-
ferent behaviour of the two drugs emitted by the same device was al-
ready discussed in the previous subsection. Finally, lung doses of Bre-
taris® Genuair® were in good and significant correlation with IV, Q and
PIFdev, in moderate and significant correlation with tb-h, but no sig-
nificant correlation with tin. Summarizing the results in Fig. 6–10, the
correlation of lung deposition with different breathing parameters
through the devices is drug and device specific. The lung dose correlates
strongly with flow rate (PIFdev and Q) for the device-drug pairs with
strong dependence of ED and FPF on the inhalation flow rate. In these
cases, there is a good correlation also with IV. The increase of breath-
hold time results in increased lung dose, but the increase is drug and
device specific. Each drug contains a certain amount of extrafine (<2
μm) particles. These particles penetrate into the lungs but they may be
exhaled if there is not enough time for them to deposit by gravitational
settling (Horváth et al., 2017). The results in Fig. 7 clearly demonstrate
the need for a better education of the patients about the high im-
portance of breath-hold after the inhalation of the drug. It is also clear
from the Fig. 9 that inhalation time correlates the least with the lung
dose. In conclusion, care should be taken when advising the patients on
which phase of the breathing manoeuvre concentrate more, because the
sensitivity of the lung dose on these phases is drug and device de-
pendant.
3.3. Correlations of lung dose with the baseline spirometric parameters
Figs. 6–9 demonstrate the possibilities of predicting the deposited
lung doses as a function of inhalation parameters that are achieved by
the COPD patients when inhaling through the devices. However, in the
clinical practice these parameters are not measured routinely. There-
fore, it is useful to study the dependence of the lung dose also on
standard spirometric parameters. Table 4 presents the correlations be-
tween the calculated doses of the four drugs deposited in the lungs of
the volunteers with FEV1 (%), FEV1 (L), FVC (%), FVC (L), FEV1/FVC
(%), PIF (L/min), PEF (L/min), and IVC (L). Based on this correlation
table, the degree of correlation between the amount of active ingredient
depositing in the lungs of the patients and baseline spirometric para-
meters is highly drug and device specific. For Symbicort® Turbuhaler®
there was significant and weak to moderate correlation with almost all
the studied parameters. The deposition of Bretaris® Genuair® correlated
significantly only with FEV1 and FVC expressed in litres and with PIF,
PEF and IVC. On the other hand, Onbreez® Breezhaler® did not exhibit
any significant correlation with the parameters considered except IVC,
while Seebri® Breezhaler® correlated with all the baseline spirometric
parameters, except FEV1/FVC (%). An important message of these re-
sults is that while for some drugs a high lung deposition can be pre-
dicted based on normal spirometric data, for other drugs this prediction
Fig. 7. Dependence of lung dose on the breath-hold time after inhalation (tb-h) in case of Symbicort® Turbuhaler® (upper left panel), Onbrez® Breezhaler® (upper
right panel), Seebri® Breezhaler® (lower left panel) and Bretaris® Genuair® (lower right panel). All the lung doses are expressed as a percent of metered dose.
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is uncertain (without numerical simulations). Another observation is
that lung deposition generally correlated better with inhalation para-
meters (PIF, IVC) than with expiratory parameters (FEV1, FVC) with the
exception of PEF. Since deposition of drugs is a result of an inhalation
manoeuvre this result seems to be logical. Therefore, it proves to be
incorrect to predict the success of drug inhalation based on these ex-
piratory parameters. In this context, especially FEV1 (%) is thought to
be a good indicator by many specialists. However, present results de-
monstrate that the correlation of lung dose with this parameter is one of
the weakest. It was also shown in one of our previous studies that for
the same patients and for the same three devices no significant corre-
lation existed between PIFdev and FEV1 (%), though FEV1 (%) corre-
lated significantly with the native PIF (Farkas et al., 2019).
3.4. Effect of gender, age and disease group
The results of two-sample t-tests carried out to study the effect of
gender on the lung deposition of COPD patients are summarized in
Table 5. The tests revealed that lung doses were consistently higher for
men than for women and the spread of values was also higher in men.
The highest difference between the mean lung dose values character-
istic of women and men was observed for Symbicort® Turbuhaler®, then
Seebri® Breezhaler® and Bretaris® Genuair®, while for Onbrez® Breez-
haler® and the difference was only minor. Significance level (p = 0.05)
was reached for Symbicort® Turbuhaler® and Seebri® Breezhaler®. It
seems that for drugs with high influence of airflow rate and inhaled
volume on the amount and size of the emitted particles the gender
difference in terms of lung doses is also higher. Interestingly, for none
of the studied drugs the mean value of lung dose was significantly
higher in the younger age group than in the older one. This observation
may virtually be in conflict with the results of Janssens et al. (2008)
who observed a decline in lung function data (especially PIF) of elderly
patients. However, the mean age in their work was 76 years, while in
our study it was only 65.7 (60.4 in the younger group and 71.3 in the
older one). Indeed, in our recent work on the statistical analysis of the
relationships between different breathing parameters of the same COPD
patients (Farkas et al., 2019) we have found no significant decrease of
PIF with age, which may partly explain the present results. Finally, the
means of lung doses were systematically higher for the GOLD B patient
group compared to the GOLD C + D group, but the differences between
the means were not statistically significant at this sample size. In
summary, men had higher lung deposition than women, younger pa-
tients had higher deposition than older ones and patients categorized
into GOLD B group higher doses than those from GOLD C + D groups
(together), but the differences were significant only for gender in case
of Symbicort® and close to significant (p = 0.08) for the same drug
upon GOLD groups. It is worth noting that splitting of Group C + D into
separate C and D groups did not change the conclusions.
3.5. The perspectives of patient tailored device choice and individual specific
optimization of drug delivery by numerical modelling in the light of the
present results
Tables 3 and 4 demonstrate that the correlation of lung dose with
native spirometric parameters is much weaker than its correlation with
the breathing parameters measured through the inhalers. As
Fig. 8. Dependence of lung dose on the inhaled air volume (IV), in case of Symbicort® Turbuhaler® (upper left panel), Onbrez® Breezhaler® (upper right panel),
Seebri® Breezhaler® (lower left panel) and Bretaris® Genuair® (lower right panel). All the lung doses are expressed as a percent of metered dose.
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measurements through inhalers are not performed routinely, the esti-
mation of the success of inhalation solely based on available baseline
spirometric data is uncertain. In addition, Table 5 indicates that it is
also not straightforward to choose the appropriate device based on the
age or GOLD group the patient belongs to. For example, based on the
present lung dose calculations it was possible to identify three different
patients from the same disease severity group (GOLD B) who had the
highest lung dose of the drug emitted by Turbuhaler®, Breezhaler® and
Genuair®, respectively. This suggests that device choice and delivery
optimization should be patient specific rather than based on patient
groups and numerical models can be a useful tool in this context. One of
the main obstacles of the use of simulations is the lack of realistic in-
haler specific breathing data for each patient. This may improve in the
future by the availability of connected devices automatically measuring
the breathing data of the patient. Airway deposition models may pro-
vide feedback on the success of inhalation in terms of the attained lung
dose based on realistic inhalation data measured by smart inhalers.
Moreover, deposition based inhaler and drug choice would be possible,
if smart probe inhalers with variable internal resistance were integrated
with airway deposition models.
Since the present results rely on empirical fits of emitted dose and
particles size fractions, the approach has its own limitations.
Unfortunately, emitted dose and particle size distribution of the cur-
rently marketed drugs are not available for arbitrary inhalation flow
profiles. Even the information on the value of these parameters at
constant flow rates is limited in the open literature. In this work, four
aerosolized drugs with relatively well documented flow rate de-
pendency of the above characteristics were chosen. However, even for
these products it was necessary to assume fitted mathematical functions
in order to tailor the emitted amount of drug and the aerodynamic
properties of the emitted particles to the special inhalation character-
istics of the individual patients. Moreover, the time dependent inhala-
tion profiles of the patients were approximated with their mean values.
A step towards a more precise approach would be to consider the pa-
tient-specific acceleration of the inspired flow, but as already men-
tioned in the methods section, this would require in vitro measurements
of emitted dose and particle size for different flow ramp-up values. In
addition, for some drugs the release of the drug is in the form of an
aerosol bolus and emission takes a shorter time than the inhalation time
of the patient. Improvement of the model to account for the possible
puff-like drug release instead of constant emission is in progress. It is
also worth noting that although the currently used aerosol deposition
model has been validated against several in vivo and in vitro measured
deposition datasets, it is still characterized by uncertainties due to the
approximations in terms of physical models, morphological data and
physiological assumptions, but also due to limited accuracy of the ap-
plied numerical schemes. All these limiting aspects should be kept in
mind when interpreting the results of numerical deposition simulations
of the deposition of inhalation drugs. Nevertheless, present study is an
important step towards a more realistic and patient specific prediction
of the deposition distribution of aerosol drugs within the human air-
ways”
4. Conclusions
The present work has demonstrated that numerical modelling based
Fig. 9. Dependence of lung dose on the inhalation time (tin) in case of Symbicort® Turbuhaler® (upper left panel), Onbrez® Breezhaler® (upper right panel), Seebri®
Breezhaler® (lower left panel) and Bretaris® Genuair® (lower right panel). The lung dose is expressed as a percent of metered dose.
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on realistic input data can be an efficient tool of predicting the de-
position distribution of aerosol drugs. The results of this study revealed
that the effect of breathing parameters on the drug dose depositing in
the lungs is not only patient and device specific but also drug specific,
as two different drugs emitted by the same device yielded different
deposition distributions. Based on the current data patients with good
spirometric parameters are likely to have high lung deposition when
inhaling a drug with emitted dose and particle size sensitive to the
inhalation flow rate (e.g. Symbicort® Turbuhaler®). Conversely, pa-
tients with lower lung capacity show better deposition results when
inhaling drugs emitting a more constant amount of drug and particles
with more stable aerodynamic characteristics. Powerful inhalation and
long breath-hold generally indicated in the patient information leaflet,
but while the first can improve the lung deposition mostly in case of
Fig. 10. Dependence of lung dose on the peak inhalation flow through the device (PIF) in case of Symbicort® Turbuhaler® (upper left panel), Onbrez® Breezhaler®
(upper right panel), Seebri® Breezhaler® (lower left panel) and Bretaris® Genuair® (lower right panel). The lung dose is expressed as a percent of metered dose.
Table 3
Correlation coefficients (r) and significance (at p = 0.05) between the computed lung doses of Symbicort® Turbuhaler®, Onbrez® Breezhaler®, Seebri® Breezhaler®
and Bretaris® Genuair® and the relevant inhalation parameters through the devices. Q – mean flow rate through the device, tb-h – breath-hold time, IV – inhaled
volume through the device; PIFdev – peak inhalation flow through the device.
Q (L/min) tb-h (s) IV (L) tin (s) PIFdev (L/min)
Symbicort® Turbuhaler® 0.95 significant 0.16 not significant 0.73 significant −0.21 not significant 0.88 significant
Onbrez® Breezhaler® 0.10 not significant 0.56 significant 0.21 not significant 0.20 not significant 0.10 not significant
Seebri® Breezhaler® 0.66 significant 0.55 significant 0.75 significant 0.10 not significant 0.60 significant
Bretaris® Genuair® 0.82 significant 0.45 significant 0.76 significant −0.49 not significant 0.81 significant
Table 4
Correlation coefficients (and significance at p = 0.05) between the computed lung doses of Symbicort® Turbuhaler®, Onbrez® Breezhaler®, Seebri® Breezhaler® and
Bretaris® Genuair® and the standard spirometric parameters. FEV1 – forced expiratory volume in the first second of exhalation, FVC – forced vital capacity, PIF – peak
inhalation flow, PEF – peak expiratory flow, IVC – inspiratory vital capacity, sig. – significant, not sig. – not significant.
FEV1 (%) FEV1 (L) FVC (%) FVC (L) FEV1/FVC (%) PIF (L/min) PEF (L/min) IVC (L)
Symbicort® Turbuhaler® 0.38 sig. 0.55 sig. 0.27 not sig. 0.52 sig. 0.34 sig. 0.46 sig. 0.57 sig. 0.33 sig.
Onbrez® Breezhaler® 0.14 not sig. 0.16 not sig. 0.19 not sig. 0.21 not sig. −0.08 not sig. 0.07 not sig. 0.09 not sig. 0.41 sig.
Seebri® Breezhaler® 0.35 sig. 0.54 sig. 0.35 sig. 0.58 sig. 0.10 not sig. 0.51 sig. 0.57 sig. 0.50 sig.
Bretaris® Genuair® 0.25 not sig. 0.42 sig. 0.25 not sig. 0.45 sig. 0.09 not sig. 0.49 sig. 0.52 sig. 0.32 sig.
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Symbicort® Turbuhaler®, the second leads to high deposition in case of
drugs emitted by Breezhaler® and Genuair®. Present results demon-
strate that for an effective therapy a more personalized drug and device
choice and breathing optimization would be necessary in the future.
Carefully validated numerical models can be a powerful tool in this
context.
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Table 5
Mean values and standard deviations of different COPD populations grouped upon gender, age and disease class.
Gender Age Disease group
women men ≤65 years >65 years GOLD B GOLD C + D
Symbicort® Turbuhaler® 26.7 (± 8.3) 20.5 (±5.3) 24.7 (± 8.7) 23.6 (± 6.9) 26.0 (± 7.9) 22.0 (± 7.4)
significant not significant not significant
Onbrez® Breezhaler® 22.7 (± 4.2) 22.5 (±2.7) 22.4 (± 3.2) 22.9 (± 4.0) 23.0 (± 3.9) 22.1 (± 3.1)
not significant not significant not significant
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